Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.

Download DocumentationJuno Corporate Presentation - January 2017
Webcast ImageWebcast - Replay
Juno Therapeutics at 35th Annual J.P. Morgan Healthcare Conference
January 10, 2017 at 4:30 p.m. PT
Juno Therapeutics at 35th Annual J.P. Morgan Healthcare Conference
Tuesday, January 10, 2017 4:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Recent News

DateTitle 
Jan. 03, 2017Juno Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
Dec. 20, 2016Juno Therapeutics’ and Celgene Corporation’s Investigational Drug JCAR017 Granted Breakthrough Therapy Designation from FDA and Priority Medicines Eligibility from EMA for Relapsed/Refractory Diffuse Large B-cell LymphomaPrinter Friendly Version
Dec. 19, 2016Juno Therapeutics Defeats Kite Pharma’s Challenge to CAR T-Cell PatentPrinter Friendly Version
Dec. 06, 2016Juno Therapeutics Highlights Progress with Best-in-Class Strategy in B-Cell Malignancies at ASHPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Past Events

DateTitle
01/10/17 4:30 p.m. PT
Juno Therapeutics at 35th Annual J.P. Morgan Healthcare Conference
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
JUNO (Common Stock)
ExchangeNASDAQ
Price$19.63
Change0.00 (0.00%)
Volume0
Data as of Jan. 20, 2017 4:00 p.m. ET